Apimeds Pharmaceuticals is a company that develops therapeutic application solutions for honeybee venom used for inflammatory conditions.
Apimeds Pharmaceuticals has raised $100.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in December 2025.
Apimeds Pharmaceuticals is headquartered in Matawan, United States.
Apimeds Pharmaceuticals is a company that develops therapeutic application solutions for honeybee venom used for inflammatory conditions.
Apimeds Pharmaceuticals is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Apimeds Pharmaceuticals — Funding & Investors." VCBacked, December 1, 2025, https://www.vcbacked.co/company/apimeds-pharmaceuticals. Accessed November 12, 2026.
VCBacked. (2025). Apimeds Pharmaceuticals — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/apimeds-pharmaceuticals
{{cite web |title=Apimeds Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/apimeds-pharmaceuticals |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Apimeds Pharmaceuticals? Request a listing update